Ciltacabtagene autoleucel

31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology indications A Media Snippet accompanying this announcement is available by clicking on this link. SOMERSET, N.J. , Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a U.S. -based global leader in cell therapy, today announced the official opening and ribbon cutting of its new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania . Located at 2300 Market Street , the 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies. The site features cutting-edge laboratories and collaborative workspaces designed to foster innovation and accelerate research programs across Legend’s oncology and immunology portfolios. “This new facility marks an exciting milestone for Legend Biotech as we continue to invest in our future and strengthen our leadership in cell therapy innovation,” said Ying Huang , Ph.D., Chief Executive Officer of Legend Biotech . “We are proud to officially open our doors in Philadelphia , a world-class hub for life sciences, where we can attract top-tier talent, collaborate with premier research institutions, and advance our mission to bring transformative therapies to patients.” The Philadelphia R&D center expands Legend’s American presence, which includes over 1,400 employees in the United States . The site will employ approximately 55 full-time team members and complements Legend’s existing R&D presence in Piscataway, New Jersey . Headquartered in Somerset, N.J. , Legend also has manufacturing activities in Raritan and Morris Plains, N.J. “The opening of our new facility represents an exciting new chapter for our research organization,” said Guowei Fang , Ph.D., President of Research and Development at Legend Biotech . “Our Philadelphia team will play a critical role in advancing our sustainable pipeline of innovative cell therapies, while strengthening collaborations within one of the nation’s most dynamic biotech ecosystems.” Local officials, academic partners, patient advocacy groups, and members of the Philadelphia biotech community gathered with Legend Biotech leadership to celebrate the ribbon-cutting ceremony and tour the new facility. “Legend Biotech’s decision to expand its R&D footprint in Philadelphia reflects the strength and momentum of our city’s life sciences ecosystem,” said Dr. Rebecca L. Grant , Director of Life Sciences & Innovation for the City of Philadelphia’s Department of Commerce . “Philadelphia is home to world-class scientific talent and research institutions, and we are proud to welcome an organization committed to pioneering therapies that change patient lives. We look forward to supporting Legend Biotech as they grow here and contribute to the continued advancement of cell and gene therapy innovation in our city.” “Philadelphia continues to be a magnet for innovation and scientific excellence,” said Chris Molineaux , CEO of Life Sciences Pennsylvania. “We are thrilled to welcome Legend Biotech to our city’s thriving life sciences community. Their investment brings high-quality jobs, research opportunities, and further reinforces Philadelphia’s growing reputation as a global leader in healthcare innovation.” About Legend BiotechWith over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. To date, CARVYKTI has been administered to over 9,000 patients with multiple myeloma at 132 treatment centers spanning 44 states across the U.S. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities. Learn more at www.legendbiotech.com and follow us on LinkedIn. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSStatements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 11, 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. INVESTOR CONTACT: Jessie Yeung Tel: (732) 956-8271jessie.yeung@legendbiotech.com PRESS CONTACT: Alexandra Ventura Tel: (732) 850-5598media@legendbiotech.com Source: Legend Biotech USA Inc.

Legend Biotech said the company and its partner, Johnson & Johnson, are now able to fully meet demand for their CAR-T therapy, Carvykti, after manufacturing expansions. Johnson & Johnson and Legend Biotech are said to have withdrawn an abstract originally planned for next month’s American Society of Hematology annual meeting comparing their CAR-T therapy, Carvykti, against Gilead Sciences and Arcellx’s forthcoming rival anito-cel.Barclays analyst Gena Wang, Ph.D., brought up the withdrawal on Legend’s third-quarter earnings call Wednesday. The presentation was a comparison between anito-cel’s iMMagine-1 and Carvykti’s Cartitude-1 and -4 trials for the treatment of multiple myeloma.  The Carvykti partners pulled the poster “due to the limited data available for anito-cel in the public domain,” Legend’s president of Carvykti, Alan Bash, explained on the call. “At this point, the abstract was withdrawn in alignment with the authors, and we are looking forward to future opportunities to share the data.” To perform the now-withdrawn analysis, J&J used a matching-adjusted indirect comparison (MAIC) approach to compare anito-cel’s late-line study to Carvykti results from both Cartitude-1 and the earlier-line Cartitude-4 trial, according to a Leerink Partners note on Nov. 4.According to Leerink, the authors indicated that a direct comparison between iMMagine-1 and Carvykti’s late-line Cartitude-1 study alone was not possible due to “limited overlap and persistent differences in key prognostic variables,” such as prior exposure to an anti-CD38 antibody and patients being refractory to their last line of therapy.The abstract asserted that patients are more likely to respond to Carvykti than to anito-cel when adjusted for baseline prognosis, according to Leerink.The Leerink analysts said they disagreed with the methodology and pointed to several flaws in the analysis, including the use of complete response and very good partial response—rather than the more stringent minimal residual disease-negativity—as the outcomes to compare efficacy.Matching patients in the trials primarily based on prior line of therapy is also flawed because of shifts in the standard of care when the trials were conducted, the team added. In addition, including data from Cartitude-4, a randomized, controlled study, likely confounded the analysis based on the patients’ available traditional options if they were selected for the trial’s control group.The anticipated launch of anito-cel next year has been the biggest concern among Legend investors lately. The rival BCMA CAR-T has demonstrated a better neurotoxicity profile and similar efficacy to Carvykti in the late-line treatment of multiple myeloma, according to a cross-trial comparison.  As anito-cel poses a late-line threat, Bash said Legend and J&J have been putting effort into convincing doctors to give Carvykti earlier in the course of the disease, when patients’ T cells are more fit to be engineered into CAR-T therapy and when the drug’s safety profile is better.Carvykti currently accounts about 60% of its overall scripts from the second- through the fourth-line patient populations, according to Bash. In the iMMagine-1 study of anito-cel, patients had received a median of four lines of prior treatment.“We’re fully ready and prepared to compete with a potential BCMA CAR-T that’s coming out potentially next year,” Bash said Wednesday.But for now, it remains difficult for Legend to comment on competitor data because the anito-cel developers have not yet reported a Kaplan-Meier curve, a graphic to visualize survival data over time, Bash said.Both J&J/Legend and Gilead/Arcellx will have data updates at ASH this year. Gilead and Arcellx investors are hoping that anito-cel will show stronger progression-free survival outcomes than Carvykti did in Cartitude-1, the Leerink analysts said in their Nov. 4 note. For most of those investors, an 18-month PFS rate of around 70% would validate anito-cel’s best-in-class profile, the team noted.Meanwhile, thanks to ongoing manufacturing expansions, Legend said it and its partner, Johnson & Johnson, can now  fully meet patient demand for Carvykti.Since Carvykti’s initial FDA approval in early 2022, supply constraints have limited the multiple myeloma treatment’s reach, forcing the companies to put some patients on wait lists.“There is no longer a wait for patients,” Bash, said on the call on Wednesday.  J&J recently started producing commercial Carvykti at its so-called Tech Lane facility in Ghent, Belgium, to supply the drug to patients in Europe. An expansion of the partners’ joint production plant in Raritan, New Jersey, is poised for approval this year to further support the U.S. market. The partners’ goal is to have the capacity to manufacture 10,000 doses annually beginning in 2026 and, eventually, 20,000 doses, Bash said.Still, Legend doesn’t expect to be able to operate with a supply surplus in the near term.“The latest data suggests that we’re really running at nearly 100% capacity utilization at all four nodes right now,” Legend CEO Ying Huang, Ph.D., said on the call, referring to the partners’ four manufacturing facilities. “So we continue to expect that all four nodes will be utilized at very high capacity next year as well.” Carvykti sales grew 84% year over year in the third quarter to $524 million, including $396 million in the U.S., where sales rose 11% sequentially.Carvykti is now being provided at 132 treatment sites in the U.S., bringing the worldwide total above 250. In the U.S., Bash said Legend is on track to cover all 180 sites that are either already offering CAR-T drugs or have started the process to administer them.The FDA’s recent removal of certain patient monitoring requirements for currently approved CAR-T therapies, plus a labeling update to include information on Carvykti’s ability to extend patients' lives in the second-line-plus setting, could drive more demand, Huang said.Legend and J&J are also working to expand the med's reach in the community healthcare setting. The partners’ sales and medical teams have recently started engaging community physicians about referring patients to receive Carvykti, Bash said. Further, the two firms are engaging with community practice networks. Virginia Oncology Associates, a private group specializing in the treatment of cancer and blood disorders, recently came on board to start treating patients with Carvykti, offering the companies an opportunity to learn about how to support these community networks, Bash said.Thanks to revenue growth and operational efficiency measures, Legend expects to achieve profitability for Carvykti by the end of 2025 and company-wide in 2026. During the third quarter, Legend reported an operating loss of $43 million, down from $70 million in the same period last year.Editor's note: The story was updated with additional information from the withdrawn study based on a Leerink Partners note.